BioStock: CombiGene raised 75MSEK through rights issue

08 April 2021 - 13:08

This week, CombiGene announced the outcome of a rights issue, which was was resolved by the board of directors on 8 March 2021 based on the authorisation from the annual general meeting held on 29 June 2020. CombiGene will receive proceeds of approximately 75 MSEK before issue costs, which means that the company can advance its preclinical program for CG01 and in vivo studies in the lipodystrophy project CGT2. CEO Jan Nilsson joined BioStock for a comment on the financing round.

Read the full interview with Jan Nilsson at

This is a pressrelease from BioStock - Connecting Innovation & Capital

Provided by: Cision
Nasdaq First North GM Stockholm (Sweden)
CombiGene AB
CombiGene is a gene therapy explorer based in Sweden. The Company is engaged in developing new methods for the treatment of neurological diseases and for epileptic patients who cannot be helped by available medical treatments at present....
Learn more about company

Related news

We use cookies to make your experience using IPOhub better. By using our site you agree to our use of cookies. Learn More